RxDoctor Payments Data

Samyuktha Muralidhara, MD

Family Medicine · Woodstock, GANPI 1841554185

Payments from drug & device makers

$3,987in general payments, 2019–2025

Across 197 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$638
  • Novo Nordisk$506
  • AstraZeneca$415
  • GSK$365
  • Boehringer Ingelheim$294
  • AbbVie$266
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,987 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$67,553
Medicare patients
254
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$105,542
MounjaroTirzepatide23$46,129
JardianceEmpagliflozin29$35,737
TrulicityDulaglutide20$24,119
FarxigaDapagliflozin Propanediol21$22,663
JanuviaSitagliptin Phosphate12$7,882
Rosuvastatin Calcium331$4,078
SynthroidLevothyroxine Sodium43$3,698
Bupropion XlBupropion Hcl85$2,405
Levothyroxine Sodium194$2,179
Atorvastatin Calcium201$2,053
Olmesartan Medoxomil85$1,615
Ezetimibe74$1,387
Lisinopril181$1,297
Losartan Potassium118$1,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$506$105,54285 claims
Lilly USA, LLCMounjaro, Trulicity$638$70,24843 claims
Boehringer IngelheimJardiance$294$35,73729 claims
AstraZenecaFarxiga$415$22,66321 claims
MerckJanuvia$53$7,88212 claims
AbbVieSynthroid$266$3,69843 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Woodstock

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →